الفهرس 
Study of the niosomal encapsulation of an anticancer drug and its effect on efficacy and safety
CONTENTOnly 14 pages are availabe for public view
 |  | from | 349 |  |  |
| | | from | 349 | | |
Abstract
Niosomes are non-ionic surfactant vesicles obtained from hydration of synthetic nonionic surfactants, with or without incorporation of cholesterol or other lipids. They are vesicular systems similar to liposomes that can be used as carriers of amphiphilic and lipophilic drugs. Niosomes are promising vehicle for drug delivery and being non-ionic; it is less toxic and improves the therapeutic index of drug by restricting its action to target cells. In niosomes, the vesicles forming amphiphile is a non-ionic surfactant such as Span 60 which is usually stabilized by addition of cholesterol and small amount of anionic surfactant such as dicetyl phosphate. They improve oral bioavailability of poorly absorbed drugs and enhance skin penetration of drugs. The surfactants are biodegradable, biocompatible, and non-immunogenic. They improve the therapeutic performance of the drug molecules by delaying the clearance from the circulation, protecting the drug from biological environment, and restricting effects to target cells. The use of nanomaterials in cancer treatment to deliver chemotherapeutic drugs and target tumors is well known. Recently, autophagy modulation mediated by nanomaterials has become an appealing notion in nano-medicine therapeutics, since it can be exploited as adjuvant in chemotherapy or in the development of a potential anti- cancer agent. IM mesylate (IM), the anti-cancer implemented in this thesis, is a protein-tyrosine kinase inhibitor that inhibits the breakpoint cluster region abelson protein (BCR-ABL) tyrosine kinase; the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in chronic myeloid leukemia. Besides IM great effectiveness, patients treated with IM may suffer from its long term toxicity as renal, cardiac and hepato-toxicity